If you are overweight or obese and already in a real caloric deficit, take 2 grams of L-carnitine tartrate per day, split with meals, for at least 12 weeks, and expect about a kilogram of extra weight loss on top of the deficit. If you are lean, healthy, and chasing a "fat burner" benefit, save your money. The evidence does not support the action.
That's the general answer. Your stack is different.
Check your whole stackFat transport, who actually benefits, and why the form on the label decides the outcome.
ConditionalIf you are overweight or obese and already in a real caloric deficit, take 2 grams of L-carnitine tartrate per day, split with meals, for at least 12 weeks.
Expect about a kilogram of extra weight loss on top of the deficit, not a transformation. If you are lean, healthy, and chasing a "fat burner" benefit, save your money. The evidence does not support the action in that population.
Real but small benefit in the right population. The form on the label decides the outcome.
Carnitine is a small molecule your body already makes from two amino acids and stores mostly in muscle. Its job is to ferry long-chain fats into the mitochondria, the part of the cell that burns fat for energy. Picture a fleet of delivery vans loading fat parcels at the cell border and driving them to the engine room. If your fleet is already full, hiring more vans does nothing. If your fleet is short or your cargo backed up (overweight, T2D, NAFLD), more vans help a small amount.
Overweight or obese adults in a real caloric deficit, T2D adjunct, NAFLD, idiopathic male infertility (sperm parameters), older adults with mild-to-moderate depression (ALC, prescriber-discussed), recreational lifters in eccentric-recovery context (LCLT plus carbs).
You are lean and healthy and want a fat burner. You are an endurance athlete chasing performance. You are about to buy premium GPLC or microencapsulated blends. You expect cognitive or vascular benefits from generic "L-carnitine."
| Population | Dose & Form | Timing | Loading |
|---|---|---|---|
| Overweight / obese, weight loss adjunct | 2 g/d L-carnitine tartrate or fumarate | Split with meals, ≥12 wk | No |
| Type 2 diabetes glycemic adjunct | 2 g/d L-carnitine | With meals, ≥8 wk | No |
| NAFLD / NASH | 1-2 g/d L-carnitine | With meals, 12-24 wk | No |
| Idiopathic male infertility (sperm parameters) | 2-3 g/d L-carnitine ± ALC | Split daily, ≥12 wk | No |
| Older adult mild-to-moderate depression (adjunct) | 1.5-3 g/d acetyl-L-carnitine (ALC) | Split daily, earlier in day | No |
| Eccentric-exercise recovery (recreational lifter) | 1-2 g/d L-carnitine-L-tartrate (LCLT) + ≥80 g CHO | Pre or peri-workout | ≥3 weeks before target sessions |
| Cancer-related fatigue (adjunct) | 2-4 g/d L-carnitine | Daily | No |
| Hepatic encephalopathy (clinician-supervised) | 4-6 g/d L-carnitine | Split, 30-90 d | No |
| Dialysis (deficiency / hypotension, supervised) | 1-2 g/d oral or 10-20 mg/kg IV | Post-dialysis if IV | No |
Oral bioavailability is saturable. A 2 gram dose absorbs about 14-18%. Higher doses absorb a smaller fraction and the rest excretes through urine. This is why dose-response plateaus near 2 grams a day.
For muscle-targeted recovery (LCLT), carbohydrate co-ingestion (≥80 grams) is part of the protocol, not an optional add-on. Insulin is what drives carnitine into muscle. Fasted supplementation raises plasma but not muscle content, which is the main reason endurance trials in trained athletes are null.
Possible INR rise (case-level signal). Monitor INR if starting carnitine on warfarin.
Valproate depletes carnitine. Co-supplementation is therapeutic, not a contraindication. Important in pediatric or chronic valproate users. Discuss with prescriber.
Not adverse. Required for muscle-targeted LCLT protocols (≥80 g CHO drives insulin-mediated muscle uptake).
EFSA 2003 Scientific Opinion concluded ≤2 g/day oral L-carnitine raises no safety concerns in adults [cite-unverified]. FDA classifies L-carnitine as Generally Recognized as Safe at typical supplement doses. Functional ceiling 3 g/day. Doses up to 4-6 g/day are used safely in supervised hepatic encephalopathy trials.
Direction of effect is real and consistent across 25 meta-analyses for body-weight in overweight/obese, T2D glycemic, NAFLD, sperm parameters, ALC depression in older adults, LCLT exercise recovery, cancer fatigue, hepatic encephalopathy, dialysis. Magnitude is small. Heterogeneity is high in body-weight pooled estimates (I² >80% in most MAs). Asbaghi 2024 GRADE-assessed analysis (PMID 38594107) places certainty at LOW-MODERATE.
Want to stop wasting money on supplements that do not deliver what the bottle says? The Verdict reviews one ingredient every week, evidence-graded, free.
SubscribeIs this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.
Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.
Get the protocolConviction-scored verdicts on supplements, nutrition, training, physio, and recovery.